Two-year data from GeNeuro’s Phase IIb ANGEL-MS extension trial to treat relapsing-remitting multiple sclerosis has shown temelimab produced a sustained neuroprotective effect and provided an early signal for clinical benefit. The results support a move into non-active progressive MS patients, according to GeNeuro S.A. (Euronext:GNRO).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,